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Abstract Vipoxin is the main toxic component in the venom of 
the Bulgarian snake Vipera ammodytes meridionalis, the most 
toxic snake in Europe. Vipoxin is a complex between a toxic 
phospholipase A2 (PLA2) and a non-toxic protein inhibitor. The 
structure is of genetic interest due to the high degree of sequence 
homology (62%) between the two functionally different compo-
nents. The structure shows that the formation of the complex in 
vipoxin is significantly different to that seen in many known 
structures of phospholipases and contradicts the assumptions 
made in earlier studies. The modulation of PLA 2 activity is of 
great pharmacological interest, and the present structure will be 
a model for structure-based drug design. 
© 1997 Federation of European Biochemical Societies. 
Key words: X-ray structure; Synchrotron radiation; Vipoxin; 
PLA 2 -complex 
1. Introduction 
Phospholipases represent a class of enzymes that catalyse 
the hydrolysis of membrane phospholipids to release free fatty 
acids. In particular, PLA 2 (EC 3.1.1.4) hydrolyses the sn-2-
acyl bond of phospholipids producing equimolar amounts of 
lysophospholipids and free fatty acids. In addition to this 
activity, PLA 2 s from snake venom include a wide variety of 
pharmacological activities such as neurotoxic effects and sep-
tic shock [1]. The ability to produce substrates for the gener-
ation of inflammatory lipid mediators in the process of tissue 
injury and rheumatoid arthritis [2] makes this specific class of 
phospholipases of medical and pharmaceutical interest. Struc-
ture-based drug design for the development of potent and 
specific inhibitors for these enzymes has led to the character-
ization and structural analysis of several PLA 2 s and their 
complexes with substrate analogues [3-11]. 
The vipoxin complex consists of an alkaline PLA 2 and an 
acidic protein inhibitor. Both, the PLA2-subunit and the in-
hibitor consist of a polypeptide chain with 122 amino acids. 
The inhibitor-subunit of vipoxin reduces phospholipase activ-
ity in vitro by up to 60% [12]. The separated PLA2-subunit is 
so far the most toxic phospholipase [13] characterized to date 
(LDi 0 0 = 1-3 (ig per 20 g mouse), and is the only PLA 2 known 
to form a complex with a highly homologous natural inhib-
itor. The high degree of sequence homology between the 
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PLA2-subunit and the inhibitor makes the complex of great 
genetic interest [14,15]. The vipoxin complex is also a neuro-
toxin with postsynaptic action, whereas all other known 
PLA 2 s exhibit a presynaptic action [13]. However, when the 
PLA2-subunit is separated as an isolated component from the 
vipoxin complex, it also exhibits presynaptic action [16]. 
2. Materials and methods 
Details of purification are available from the authors. Crystals with 
high quality were grown within two weeks at 20°C by sitting drop 
technique from a solution with a final composition of 14% PEG 3350, 
15% PEG 400, 10 mM CaCl2, 100 mM Na acetate at pH 4.8 contain-
ing 12 mg/ml Protein. One crystal was used to collect data up to 2.0 A. 
All diffraction measurements were performed at — 172°C on a flash 
frozen crystal of approximate dimensions of 0.2X0.1 X 1.5 mm3. Dif-
fraction data were collected at EMBL-Hamburg, synchrotron beam 
line BW7B using a MAR Image Plate Scanner. The space group was 
assigned as Y2{2{2 with one molecule in the asymmetric unit. The cell 
dimensions are pseudotetragonal with a = 67.64, 6 = 67.69 and 
c = 46.82 A, giving a packing parameter VM of 2.0. The images were 
processed using the DENZO program package [19] with a resulting 
Bsymm = 8.6%. The phase problem was solved by molecular replace-
ment techniques applying the program AmoRe [20] and one monomer 
of the dimeric phospholipase A2 from Crotalus atrox (pdb entry = 1 
PP2) as search model. The initial structure was refined by the max-
imum likelihood method using the program refmac [21]. The present 
crystallography R factor is 0.16 (Rfrcc is 0.23) using all data between 
20.0 and 2.0 A including 285 water molecules and one acetate. On 
average, bond lengths, interbond angle distances and planarities de-
viate from ideality by 0.013, 0.034 and 0.025 A, respectively. 
3. Results and discussion 
We can show, that as expected from the extensive sequence 
homology (Fig. 1) the overall fold and disulphide network are 
similar to other known PLA 2 s . As shown in Fig. 2, the struc-
tures of vipoxin-PLA2-subunit and the inhibitor can both be 
closely superimposed on a PLA 2 from Crotalus atrox [11] with 
an r.m.s. difference for the C a positions of 1.48 and 1.46 A, 
respectively. 
One of the most striking features of the vipoxin complex is 
the manner in which the complex is formed. The reported 
structures of PLA 2 from Crotalus atrox, and recently the 
structure of the isolated inhibitor of vipoxin [17] show that 
both form dimers with an almost exact two-fold rotational 
symmetry. Based on this arrangement Devedjiew et al. [17] 
have proposed a model for the vipoxin complex with a similar 
complex conformation. However the structure presented here 
shows that this is not the case and that the relative positions 
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a a a a a a a 
Asn Leu Phe Gin Phe Ala Lys Met 
Asn Leu Phe Gin Phe Gly Asp Met 
Ser Leu Val Gin Phe Glu Thr Leu 
a 
lie 
He 
He 
10 
a a a 
Asn Gly Lys 
Leu Gin Lys 
Met Lys He 
30 
a a 
Leu Gly 
Thr Gly 
Ala Gly 
- Ala Phe 
- Lys Glu 
Arg Ser 
20 
Ser Val Trp 
Ala Val His 
Gly Leu Leu 
40 
Asn Tyr He Ser 
Ser Tyr Ala He 
Trp Tyr Ser Ala 
a a a a 
Thr Asp Arg Cys 
Thr Asp Arg Cys 
Thr Asp Arg Cys 
Tyr Gly Cys Tyr Cys Gly Trp Gly Gly Gin 
Tyr Gly Cys Tyr Cys Gly Trp Gly Gly Gin 
Tyr Gly Cys Tyr Cys Gly Trp Gly Gly His 
50 
a a a « » « a a * a a 
Cys Phe Val His Asp Cys 
Cys Phe Ala Gin Asp Cys 
Cys Phe Val His Asp Cys 
70 
a 
Gly Thr Pro Lys Asp Ala 
Gly Arg Ala Gin Asp Ala 
Gly Leu Pro Gin Asp Ala 
60 
Cys - - - - - Asn Pro Lys Leu 
Cys - Asn Pro Lys Thr 
Cys - Asn Pro Lys Thr 
90 
P P P P P a a 
Asn lie Val Cys Gly Lys - Asn Asn Gly 
Asp He Val Cys Gly Asp - Asp Asp Leu 
Glu He He Cys Gly Gly - Asp Asp Pro 
110 
Cys Tyr Gly Arg Val Arg -
Cys Tyr Gly Arg Val Asn -
Cys Tyr Gly Lys Ala Thr -
P P P P 
Ala He Tyr Ser Tyr Ser Phe 
Ala Thr Tyr Thr Tyr Ser Phe 
Val Ser Tyr Thr Tyr Ser Glu 
- Gly -
- Asp -
- Asp -
80 
P P P 
Lys Lys Gly 
Glu Asn Gly 
Glu Asn Gly 
100 
a a a a 
Cys Leu Arg Asp 
Cys Leu Arg Ala 
Cys Gly Thr Gin 
a a a a • a 
He Cys Glu Cys Asp Arg 
Val Cys Glu Cys Asp Arg 
He Cys Glu Cys Asp Lys 
120 
a a a a 
Val Ala Ala Asn 
Ala Ala Ala He 
Ala Ala Ala He 
a a a a a 
Cys Phe His Gin Asn Lys Asn Thr Tyr Asn Arg Asn Tyr Lys Phe Leu 
Cys Leu Gly Glu Asn Val Asn Thr Tyr Asp Lys Asn Tyr Glu Tyr Tyr 
Cys Phe Arg Asp Asn He Pro Ser Tyr Asp Asn Lys Tyr Trp Leu Phe 
130 
PLA2 Vipoxin Ser Ser - Ser Arg Cys Arg Gin Thr Ser Glu Gin Cys 
Inh. Vipoxin Ser Ser - Ser His Cys Thr Glu Glu Ser Glu Gin Cys 
PLA2 C. Atrox Pro Pro - Lys Asp Cys Arg Glu Glu Pro Glu Pro Cys 
Fig. 1. Sequence comparison showing the sequences of the vipoxin-PLA2, the vipoxin inhibitor and the Crotalus atrox PLA2 [11]. The sequence 
numbering refers to the bovine pancreatic PLA2 [10] accordance to the numbering scheme commonly adopted in literature. Catalytic site resi-
dues (ovals), the residues supposed to be involved in a potential calcium binding (squares), and the regions of secondary structure are indicated 
accordingly. 
of the two subunits are significantly different to other dimeric 
PLA2S and most interestingly also to the isolated inhibitor. In 
the vipoxin complex one subunit is rotated by about 180° to 
give a pseudo mirror symmetry (Fig. 3) and the complex is 
stabilized by twelve intermolecular contacts which obviously 
differ from those in the dimeric PLA2 from Crotalus atrox 
(Table 1). Furthermore there is no evidence for the complex 
'recognition site' involving residues Phe3, Trp31 and Tyr119 of 
the inhibitor as proposed by Devedjiew. Table 1 summarises 
the contacts found in the vipoxin complex in comparison to 
those found in the dimer of Crotalos atrox PLA2. 
The lack of activity for the inhibitor is explained by the 
replacement of the catalytically essential His48 by glutamin 
(Fig. 1) whereas in the PLA2-subunit the side chains of 
His48, Asp" and Tyr52 (Fig. 4) form an active site which is 
conserved in all phospholipases [3-11]. However, in the vipox-
in-PLA2-subunit, the region referred to be the calcium-bind-
ing loop is structurally different from other PLA2s. The Ca
2+-
binding region found in the refined crystal structure of bovine 
PLA2 [10] and of human PLA2 [8] the three backbone carbon-
yl oxygens of Tyr28, Gly30 and Gly32 and the carboxylate 
group of Asp49 form a Ca2+ coordination site. This confor-
mation is not possible in the PLA2-subunit, because the back-
bone carbonyl oxygens of Tyr28 and Gly32 (Table 1) are al-
ready involved in intermolecular contacts with the inhibitor. 
Moreover, the carbonyl oxygen of Gly32 (PLA2) is about 5.5 A 
apart from the potential calcium-binding site. Based on the 
Ca2+-free structure of PLA2 from Crotalus atrox, Keith et al. 
[11] have suggested that the positively charged alkylammo-
nium side chain of Lys69 may satisfy the need for partial 
charge neutralisation in the region of the structurally shielded 
Asp49 carboxylate. Also in vipoxin there is an ionic interac-
tion between Lys69 (Inhibitor) and Asp49 (PLA2). The binding 
of calcium by the PLA2-subunit would require a change in the 
conformation of the complex, which would weaken the stabil-
ity of the complex. The requirement of Ca2+ for activity needs 
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Fig. 2. Stereo-plot showing the superimposed Ca-backbone structures of the phosphohpases A2 of vipoxin (red), and from Crotalus atrox 
(green) and the Vipoxin inhibitor (blue). The three a-helices fit very close. Only in the region 65-75 of the flexible p-sheet and the area around 
the potential Ca2+o binding loop (residues 27-33) higher deviations are visible. The r.m.s. deviations for the Ca positions using Vipoxin-PLA2 
as target are 1.48 A for the inhibitor and 1.50 A for the PLA2 from Crotalus atrox. 
further discussion as, although greatly reduced, the PLA2-sub-
unit in complex with the inhibitor still shows enzyme activity 
in the absence of calcium. 
White et al. [7] have reported the crystal structure of Cobra-
Venom PLA2 in complex with a phosphonate transition-state-
analogue which shows the interactions in the active site. For 
vipoxin the electron density maps have clearly shown the 
presence of an acetate, originating from the crystallization 
medium, in the active site. Acetate is the terminal part of a 
fatty acid and therefore it is interesting to note that this ace-
tate is recognized in the position of the free fatty acid after 
cleavage of the 2-sn-acyl bond [7]. Fig. 4 shows that the ace-
tate forms hydrogen bonds with His48 and Gly30 as well to-
wards a water molecule in the active site. Considering the 
absence of calcium and the remaining reduced activity, this 
is an indication for an active site coordinated substrate-ana-
logue. No acetate is found in the corresponding position of 
the inhibitor as might be expected due to the missing histidine 
in position 48. 
The vipoxin complex displays bifunctional behaviour. 
Whilst the phospholipase activity is reduced by up to 60% if 
complexed with the inhibitor, it has also been shown that, 
when separated from the inhibitor, the phospholipase soon 
irreversibly loses its enzymatic activity [16]. Similarly, the neu-
rotoxic activity of vipoxin in complex persists for at least four 
years, whereas it is lost within some days after separation of 
the complex [12]. Snake venom contains several phosphoh-
pases and in the case of vipoxin, importance is placed on 
preservation of toxicity. Thus, the inhibitor provides stability 
to sustain the toxicity for long periods at the expense of 
phospholipase activity. Nature has found a compromise be-
tween these two biological functions. The crystal structure of 
the vipoxin complex reveals the molecular interactions, which 
effect these modifications of biological functions. 
To elucidate the new and upcoming aspects in the structure 
function relationship of vipoxin further X-ray studies to high 
resolution, including studies of complexes with bound sub-
strate analogues are intended. 
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Table 1 
Intermolecular contacts stabilizing the Vipoxin-complex in comparison to contacts in the dimeric PLA2 complex of Crotalus atrox 
Vipoxin 
Atom of F 
Asn1 
Asn1 
Phe3 
Tyr28 
Trp31 
Gly32 
Asp49 
Asp49 
Val55 
Gly69 
Cys61 
Lys69 
'LA2 
N52 
N82 
N 
0 
Ne 
0 
081 
052 
O 
0 
081 
NC 
Atom of inhibitor 
Gly33 
Gin34 
Gly32 
Lys69 
Lys12 
Leu2 
Lys69 
Lys69 
Asn56 
Asn56 
Asp49 
Cys29 
O 
Oel 
O 
N? 
O 
N 
N? 
NC 
N82 
N82 
O 
O 
Distance 
(A) 
3.1 
2.9 
2.8 
2.7 
3.1 
3.0 
2.9 
3.0 
2.6 
3.3 
2.8 
3.2 
Dimer of PLA2 from Crotalus atrox 
Atom of PLA2 
Chain R 
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Chain L 
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Trp31 
Glu6 
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2.5 
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Fig. 3. A cartoon plot of the overall structure of the vipoxin complex (PLA2 in blue and inhibitor in red). Based on the orientation of the vi-
poxin-PLA2, the dimeric PLA2 from Crotalus atrox is superimposed and only the part of the dimer corresponding to the inhibitor is shown (in 
white and dashed lines). The relative position of the inhibitor to the corresponding PLA2 from Crotalus atrox is obviously different. The draw-
ing was created by the program MOLSCRIPT [18]. 
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lines. 
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